arrow
R

Romain Guièze

centre hospitalier universitaire de clermont-ferrand
H指数:27
被引数:2,818

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Response to two comments on “EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation” by S. Molica and A. Tedeschi: Beyond the binary choice

针对S. Molica和A. Tedeschi关于“EHA慢性淋巴细胞白血病和Richter转化的管理指南”的两篇评论的回应:超越二元选择

2026-10-110
OAAI
Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study

老年(≥60岁)FLT3突变急性髓系白血病患者采用含或不含Midostaurin的强化化疗:一项FILO-DATAML-PETHEMA真实世界研究

2026-02-110
OAAI
Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group

可测量残留病灶指导下的伊布替尼联合维奈克拉方案与FCR方案在初治中危慢性淋巴细胞白血病患者中的比较:一项来自FILO研究组的随机对照II期临床试验(ERADIC)。

2025-12-170
OAAI
Optimizing Wilms tumor 1 thresholds for measurable residual disease monitoring in acute myeloid leukemia: Improved sensitivity and concordance with nucleophosmin 1 in a single-center validation study

优化Wilms tumor 1阈值以监测急性髓系白血病中的可测量残留疾病:单中心验证研究中提高了与nucleophosmin 1的敏感性和一致性

Cancer
IF5.1
2025-10-260
PRE
Correction to: Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS)

更正:Acalabrutinib在慢性淋巴细胞白血病中的真实世界有效性和安全性结局:一项法国多中心观察性研究(NAOS)的主要结果

2025-10-130
OA
Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)

地塞米松添加到新诊断急性髓系白血病老年患者的诱导和缓解后治疗中:一项多中心、II期试验(DEXAML-02)

2025-10-011
OAAI
Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS)

阿卡巴鲁替尼在慢性淋巴细胞白血病中的真实世界有效性与安全性结局:一项法国多中心观察性研究(NAOS)的主要结果

2025-07-300
OAAI
Superoxide-mediated phosphorylation and stabilization of Mcl-1 by AKT underlie venetoclax resistance in hematologic malignancies

超氧化物介导的AKT对Mcl-1的磷酸化与稳定化是维奈克拉耐药性的基础,在血液系统恶性肿瘤中。

Leukemia
IF13.4
2025-07-240
OAAI
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病患者的治疗策略和治疗顺序: 欧洲CLL研究计划ERIC的国际研究

2024-09-170
OAAI
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trial
2024-08-090
OAAI
Molecular landscape of mature B-cell lymphoproliferative disorders with BCL3-translocation: A Groupe Francophone de Cytogénétique Hématologique (GFCH)/French Innovative Leukemia Organization (FILO) study
2024-05-300
PRE
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma
2024-02-220
OAAI
Prevalence of FGF23 elevation in patients with hypophosphatemia
2024-02-010
PRE
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study
2024-01-260
OAAI
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort
2024-01-102
OAAI
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies
2023-11-1512
OAAI
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

CLL历史上的其他恶性肿瘤: ERIC进行的一项国际多中心研究,欧洲CLL研究倡议,和谐

2023-11-016
OAAI